Your browser is no longer supported. Please, upgrade your browser.
Settings
REPH Recro Pharma, Inc. daily Stock Chart
REPH [NASD]
Recro Pharma, Inc.
Index- P/E- EPS (ttm)-2.15 Insider Own0.90% Shs Outstand18.77M Perf Week-2.62%
Market Cap181.13M Forward P/E- EPS next Y-2.99 Insider Trans-78.18% Shs Float17.67M Perf Month13.80%
Income-36.40M PEG- EPS next Q-0.90 Inst Own78.60% Short Float4.04% Perf Quarter26.31%
Sales70.20M P/S2.58 EPS this Y-912.60% Inst Trans-4.05% Short Ratio6.54 Perf Half Y44.89%
Book/sh2.61 P/B3.70 EPS next Y-32.30% ROA-20.90% Target Price16.67 Perf Year45.99%
Cash/sh2.20 P/C4.39 EPS next 5Y- ROE-60.00% 52W Range5.81 - 10.59 Perf YTD19.73%
Dividend- P/FCF- EPS past 5Y-36.00% ROI-25.70% 52W High-8.88% Beta-0.48
Dividend %- Quick Ratio1.40 Sales past 5Y- Gross Margin43.80% 52W Low66.09% ATR0.45
Employees195 Current Ratio1.60 Sales Q/Q0.60% Oper. Margin-53.50% RSI (14)58.13 Volatility5.98% 5.05%
OptionableYes Debt/Eq0.50 EPS Q/Q4.80% Profit Margin-51.90% Rel Volume0.53 Prev Close9.70
ShortableYes LT Debt/Eq0.50 EarningsNov 09 Payout- Avg Volume109.14K Price9.65
Recom1.70 SMA204.52% SMA507.39% SMA20020.80% Volume57,797 Change-0.52%
Dec-19-16Initiated Piper Jaffray Overweight $12
Nov-14-16Initiated Aegis Capital Buy $21
Oct-03-16Resumed Brean Capital Buy
Sep-16-16Initiated ROTH Capital Buy
Nov-24-15Resumed H.C. Wainwright Buy $14
Sep-02-15Initiated H.C. Wainwright Buy $19
Jun-18-15Reiterated Brean Capital Buy $26 → $28
Apr-14-15Reiterated MLV & Co Buy $12 → $22
Jun-12-14Initiated Aegis Capital Buy $40
Mar-20-14Initiated Brean Capital Buy $26
Nov-20-17 07:00AM  Recro Pharma Secures $100 Million Credit Facility GlobeNewswire
Nov-09-17 09:37AM  Recro Pharma reports 3Q loss Associated Press
07:00AM  Recro Pharma Reports Third Quarter 2017 Financial Results GlobeNewswire
Nov-08-17 07:00AM  Recro Pharma to Present at Upcoming Investor Conferences GlobeNewswire
Oct-31-17 07:00AM  Recro Pharma Reports Inducement Grants for New Staff GlobeNewswire
Oct-10-17 07:00AM  Recro Pharma Presents Phase III IV Meloxicam Clinical Efficacy Data in Patients Following Abdominoplasty at the 2017 American Society of Plastic Surgeons Annual Meeting GlobeNewswire
Oct-09-17 11:59AM  ETFs with exposure to Recro Pharma, Inc. : October 9, 2017 Capital Cube
Oct-06-17 09:12AM  Recro Pharma, Inc. :REPH-US: Earnings Analysis: Q2, 2017 By the Numbers : October 6, 2017 Capital Cube
Oct-05-17 05:00PM  Recro Pharma to Participate in Upcoming Investor Conferences GlobeNewswire
07:00AM  Recro Pharma Announces PDUFA Date for IV Meloxicam 30mg GlobeNewswire
Sep-29-17 07:00AM  Recro Pharma Reports Inducement Grants for New Staff GlobeNewswire
Sep-28-17 07:00AM  Recro Pharma Announces FDA Acceptance for Review of New Drug Application for IV Meloxicam 30mg GlobeNewswire
Sep-05-17 07:00AM  Recro Pharma Presents Phase III IV Meloxicam Clinical Safety and Opioid Use Data at PAINWeek® 2017 GlobeNewswire
Aug-25-17 10:45AM  Adamas (ADMS) Dyskinesia Drug Gets FDA Approval, Stock Soars Zacks
Aug-24-17 10:57AM  Lannett (LCI) Q4 Earnings In Line, Stock Up on Solid View Zacks
Aug-21-17 07:00AM  Recro Pharma Appoints Jyrki Mattila as Executive Vice President of Business Development GlobeNewswire
Aug-10-17 11:51PM  Recro Pharma reports 2Q loss Associated Press
03:00PM  Recro Pharma Reports Inducement Grants for New Staff GlobeNewswire
07:00AM  Recro Pharma Reports Second Quarter 2017 Financial Results GlobeNewswire
Jul-31-17 07:00AM  Recro Pharma Submits New Drug Application for IV Meloxicam 30mg GlobeNewswire
Jul-21-17 07:00AM  Recro Pharma Reports Inducement Grants for New Staff GlobeNewswire
Jul-10-17 07:00AM  Recro Pharma Reports Inducement Grants for New Staff GlobeNewswire
Jul-05-17 08:00AM  Recro Pharma Acquires Novel Neuromuscular Blocking Agents GlobeNewswire
Jun-26-17 07:00AM  Recro Pharma Added to the Russell 3000® Index GlobeNewswire
Jun-16-17 04:14PM  ETFs with exposure to Recro Pharma, Inc. : June 16, 2017 Capital Cube
07:00AM  Recro Pharma to Participate in Hospital Drug Launch Panel at the JMP Life Sciences Conference GlobeNewswire
Jun-15-17 07:00AM  Recro Pharma Reports Inducement Grants for New Staff GlobeNewswire
Jun-14-17 09:29AM  Recro Pharma, Inc. :REPH-US: Earnings Analysis: Q1, 2017 By the Numbers : June 14, 2017 Capital Cube
Jun-06-17 07:00AM  Recro Pharma Appoints Ryan D. Lake as Senior Vice President of Finance and Chief Accounting Officer GlobeNewswire
Jun-02-17 07:00AM  Recro Pharma to Participate in Upcoming Investor Conferences GlobeNewswire
May-18-17 08:00AM  Recro Pharma Presents Phase III Bunionectomy Clinical Data for IV Meloxicam at the American Pain Society 36th Annual Scientific Meeting GlobeNewswire
May-15-17 07:00AM  Recro Pharma to Present Phase III Bunionectomy Clinical Data for IV Meloxicam at the American Pain Society 36th Annual Scientific Meeting GlobeNewswire +7.21%
May-11-17 09:04AM  Recro Pharma reports 1Q loss Associated Press
07:00AM  Recro Pharma Reports First Quarter 2017 Financial Results GlobeNewswire
May-09-17 07:00AM  Recro Pharma Announces Successful Top-Line Results from Phase III Safety Study of IV Meloxicam GlobeNewswire
Apr-07-17 05:22PM  ETFs with exposure to Recro Pharma, Inc. : April 7, 2017 Capital Cube
Mar-29-17 07:00AM  Recro Pharma to Present at the 16th Annual Needham Healthcare Conference GlobeNewswire
Mar-17-17 09:23AM  Recro Pharma, Inc. :REPH-US: Earnings Analysis: Q4, 2016 By the Numbers : March 17, 2017 Capital Cube
09:23AM  Recro Pharma, Inc. :REPH-US: Earnings Analysis: Q4, 2016 By the Numbers : March 17, 2017
Mar-16-17 10:16AM  Recro Pharma, Inc. :REPH-US: Earnings Analysis: 2016 By the Numbers : March 16, 2017 Capital Cube
10:16AM  Recro Pharma, Inc. :REPH-US: Earnings Analysis: 2016 By the Numbers : March 16, 2017
07:00AM  Recro Pharma to Present at the Oppenheimer 27th Annual Healthcare Conference GlobeNewswire
Mar-15-17 01:04PM  RECRO PHARMA, INC. Financials
Mar-09-17 03:04PM  RECRO PHARMA, INC. Files SEC form 10-K, Annual Report
Mar-07-17 06:04AM  RECRO PHARMA, INC. Files SEC form 8-K, Results of Operations and Financial Condition, Other Events, Financial Stateme
Mar-06-17 04:05PM  Recro Pharma Reports Year End 2016 Financial Results GlobeNewswire
02:21PM  RECRO PHARMA, INC. Files SEC form 8-K, Change in Directors or Principal Officers, Other Events, Financial Statements
07:00AM  Recro Pharma Appoints Bryan Reasons to Its Board of Directors GlobeNewswire
Mar-02-17 07:00AM  Recro Pharma to Present at Upcoming Investor Conferences GlobeNewswire
Feb-27-17 09:18AM  RECRO PHARMA, INC. Files SEC form 8-K, Other Events, Financial Statements and Exhibits +7.25%
07:00AM  Recro Pharma Completes Enrollment in Phase III Safety Study of IV Meloxicam GlobeNewswire
Jan-18-17 02:50PM  Exclusive: Recro Pharma CEO Talks Meloxicam, Alleviating Investor Concerns Benzinga
Jan-06-17 04:32PM  RECRO PHARMA, INC. Files SEC form 8-K, Other Events, Financial Statements and Exhibits
Dec-19-16 06:48AM  Coverage initiated on Recro Pharma by Piper Jaffray
Dec-16-16 04:03PM  RECRO PHARMA, INC. Files SEC form 8-K, Other Events
09:27AM  Recro Pharma Announces Closing of $40 Million Public Offering of Common Stock GlobeNewswire
Dec-15-16 08:23PM  Is ModusLink Global Solutions, Inc. (MLNK) A Good Stock to Buy? at Insider Monkey -5.37%
06:28PM  How Intrepid Potash, Inc. (IPI) Stacks Up Against Its Peers at Insider Monkey
02:12PM  5 Stocks Insiders Love Right Now
Dec-13-16 01:00PM  Here's how a Malvern pharma firm plans to spend its $36M in stock proceeds at bizjournals.com +9.32%
09:10AM  Recro Pharma Announces Pricing of Public Offering of Common Stock GlobeNewswire
Dec-12-16 02:50PM  ETFs with exposure to Recro Pharma, Inc. : December 12, 2016 -6.75%
Dec-08-16 11:50AM  Recro Pharma Secondary Offering (UPDATE) -5.44%
09:02AM  Recro Pharma Announces Proposed Public Offering of Common Stock GlobeNewswire
06:31AM  RECRO PHARMA, INC. Files SEC form 8-K, Entry into a Material Definitive Agreement, Financial Statements and Exhibits
Dec-01-16 11:25AM  Recro Pharma Files for Secondary Offering Following Big Late-Stage Win -19.00%
Nov-30-16 10:02AM  RECRO PHARMA, INC. Files SEC form 8-K, Other Events, Financial Statements and Exhibits -8.15%
Nov-29-16 03:13PM  Recro Pharma Inc (REPH): Heres Whats Next at Insider Monkey -6.34%
10:25AM  Recro Pharma Pain Drug Does Well In Study (REPH) at Investopedia
10:10AM  Company News for November 29, 2016
08:25AM  Recro Pharma (REPH) in Focus: Stock Moves 19.8% Higher
08:15AM  Blog Coverage Recro Pharma Shares Soared Nearly 20% after Reporting Positive Top-Line Results from Pivotal Phase III Clinical Trial of IV Meloxicam Accesswire
Nov-28-16 12:20PM  Recro Pharma Rises on Late Stage Win +19.85%
08:43AM  Recro Pharma surges 19% after positive late-stage trial for non-opioid pain treatment at MarketWatch
07:20AM  RECRO PHARMA, INC. Files SEC form 8-K, Other Events, Financial Statements and Exhibits
07:00AM  Recro Pharma Reports Positive Top-Line Results from Pivotal Phase III Clinical Trial of IV Meloxicam GlobeNewswire
Nov-15-16 10:03AM  RECRO PHARMA, INC. Files SEC form 8-K, Other Events, Financial Statements and Exhibits
Nov-11-16 05:00AM  Recro Pharma reports 3Q loss +7.06%
Nov-10-16 02:30PM  RECRO PHARMA, INC. Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements and Exhibi
09:05AM  RECRO PHARMA, INC. Files SEC form 10-Q, Quarterly Report
07:14AM  Peek Into Drug Stocks' Q3 Earnings on Nov 11: XBIT & REPH
07:00AM  Recro Pharma Reports Third Quarter 2016 Financial Results GlobeNewswire
Nov-09-16 07:00AM  Recro Pharma to Present at Upcoming Investor Conferences GlobeNewswire
Oct-03-16 10:34AM  Recro Pharma Offers A Non-Opioid Alternative For Pain Management; Brean Assumes With Buy Rating
Sep-12-16 07:47AM  RECRO PHARMA, INC. Files SEC form 8-K, Other Events, Financial Statements and Exhibits
Sep-08-16 08:12AM  RECRO PHARMA, INC. Files SEC form 8-K, Regulation FD Disclosure, Other Events, Financial Statements and Exhibits
Sep-07-16 04:05PM  Recro Pharma Presents Clinical Data at PAINWeek 2016 GlobeNewswire
Sep-06-16 11:10AM  ETFs with exposure to Recro Pharma, Inc. : September 6, 2016
07:00AM  Recro Pharma to Present at the Rodman & Renshaw 18th Annual Global Investment Conference GlobeNewswire
Aug-19-16 10:38AM  Recro Pharma Announces Closing of Public Offering of Common Stock GlobeNewswire
Aug-18-16 01:15PM  Recro Pharma Inc. (REPH): Largest Shareholder Broadfin Capital Buys Even More Shares at Insider Monkey
Aug-17-16 06:10AM  RECRO PHARMA, INC. Files SEC form 8-K, Entry into a Material Definitive Agreement, Financial Statements and Exhibits
Aug-16-16 09:00AM  Recro Pharma Announces Pricing of Public Offering of Common Stock GlobeNewswire
Aug-15-16 06:06PM  Recro Pharma Announces Proposed Public Offering of Common Stock GlobeNewswire
Aug-12-16 12:40PM  RECRO PHARMA, INC. Files SEC form 8-K, Results of Operations and Financial Condition, Other Events, Financial Stateme
11:19AM  Recro Pharma, Inc. :REPH-US: Earnings Analysis: Q2, 2016 By the Numbers : August 12, 2016
Aug-11-16 08:03AM  RECRO PHARMA, INC. Files SEC form 10-Q, Quarterly Report
07:23AM  Recro Pharma reports 2Q loss
07:00AM  Recro Pharma Reports Second Quarter 2016 Financial Results GlobeNewswire
Jul-27-16 03:00PM  A Look At Recro Pharma Inc (REPH) and Alkermes Plc (ALKS)s Topline Triumph at Insider Monkey +28.91%
Recro Pharma, Inc., a specialty pharmaceutical company, engages in developing non-opioid products for the treatment of acute pain primarily in the United States. Its lead product candidate includes injectable meloxicam, which completed pivotal Phase III clinical trials for the treatment of post-operative pain. The company also provides Dex-IN, an intranasal formulation of dexmedetomidine that is in development stage for treating post-operative pain and peri-procedural pain; and Fadolmidine, alpha-2 agonist product for use in treating neuropathic pain. It also provides contract development and manufacturing services. It has a license agreement with Orion Corporation for the development and commercialization of Non-Injectable Dexmedetomidine. The company focuses on offering its products for hospitals and related markets. The company was formerly known as Recro Pharma I, Inc. and changed its name to Recro Pharma, Inc. in August 2008. Recro Pharma, Inc. was founded in 2007 and is based in Malvern, Pennsylvania.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Broadfin Healthcare Master Fun10% OwnerDec 05Sale10.00100,0001,000,0002,605,262Dec 07 04:14 PM
Broadfin Healthcare Master Fun10% OwnerNov 30Sale9.56168,4031,610,2172,705,262Nov 30 05:38 PM
Broadfin Healthcare Master Fun10% OwnerNov 29Sale9.676,66464,4322,873,665Nov 30 05:38 PM
Broadfin Healthcare Master Fun10% OwnerNov 28Sale9.6447,549458,4132,880,329Nov 30 05:38 PM
Broadfin Healthcare Master Fun10% OwnerNov 24Sale9.3718,114169,7352,927,878Nov 24 01:32 PM
Broadfin Healthcare Master Fun10% OwnerNov 22Sale9.3751,654483,9672,945,992Nov 24 01:32 PM
Broadfin Healthcare Master Fun10% OwnerNov 21Sale9.50102,440972,8632,997,646Nov 24 01:32 PM
Flynn James EPossible Member of 10% GroupJun 14Sale6.2568,000425,0001,176,685Jun 14 08:13 PM
Flynn James EPossible Member of 10% GroupJun 13Sale6.5932,447213,8261,244,685Jun 14 08:13 PM
Flynn James EPossible Member of 10% GroupJun 12Sale6.7410,00067,4001,277,132Jun 14 08:13 PM
Flynn James EPossible Member of 10% GroupJun 08Sale6.9917,245120,5431,287,132Jun 09 04:07 PM
Flynn James EPossible Member of 10% GroupJun 07Sale7.0945,623323,4671,304,377Jun 09 04:07 PM
Stonepine Capital Management, 10% OwnerMay 12Sale7.40510,0003,774,2041,902,380May 15 05:33 PM
Stonepine Capital Management, 10% OwnerMay 11Sale7.969,00071,6822,412,380May 11 07:06 PM
Stonepine Capital Management, 10% OwnerMay 10Sale7.777,50058,2952,421,380May 11 07:06 PM
Stonepine Capital Management, 10% OwnerMay 09Sale7.64228,1291,741,7882,428,880May 11 07:06 PM
Stonepine Capital Management, 10% OwnerMay 04Sale7.69201,1601,547,1222,657,009May 05 06:13 PM
Stonepine Capital Management, 10% OwnerMay 03Sale7.7916,148125,8402,858,169May 05 06:13 PM
SCP Vitalife Partners II LP10% OwnerMar 16Sale7.939,48875,2002,247,922Mar 16 05:35 PM
SCP Vitalife Partners (Israel)10% OwnerMar 16Sale7.933,17025,125751,093Mar 16 05:37 PM
SCP Vitalife Partners (Israel)10% OwnerMar 15Sale8.016,39951,270754,263Mar 16 05:37 PM
SCP Vitalife Partners II LP10% OwnerMar 15Sale8.0119,161153,5222,257,410Mar 16 05:35 PM
SCP Vitalife Partners II LP10% OwnerMar 14Sale8.0416,328131,2712,276,571Mar 16 05:35 PM
SCP Vitalife Partners (Israel)10% OwnerMar 14Sale8.045,45443,848760,662Mar 16 05:37 PM
SCP Vitalife Partners (Israel)10% OwnerFeb 17Sale7.593,33425,312766,116Feb 21 04:16 PM
SCP Vitalife Partners II LP10% OwnerFeb 17Sale7.599,98375,7912,292,899Feb 21 04:15 PM
SCP Vitalife Partners II LP10% OwnerFeb 16Sale7.863,29325,8742,302,882Feb 17 04:29 PM
SCP Vitalife Partners (Israel)10% OwnerFeb 16Sale7.861,1008,643769,450Feb 17 04:29 PM
SCP Vitalife Partners (Israel)10% OwnerFeb 15Sale7.882,16417,052770,550Feb 17 04:29 PM
SCP Vitalife Partners II LP10% OwnerFeb 15Sale7.886,47951,0552,306,115Feb 17 04:29 PM
SCP Vitalife Partners II LP10% OwnerFeb 14Sale7.962,29318,2432,312,594Feb 17 04:29 PM
SCP Vitalife Partners (Israel)10% OwnerFeb 14Sale7.967666,094772,714Feb 17 04:29 PM
SCP Vitalife Partners (Israel)10% OwnerFeb 13Sale7.972,65121,130773,480Feb 15 04:16 PM
SCP Vitalife Partners II LP10% OwnerFeb 13Sale7.977,93763,2612,314,887Feb 15 04:15 PM
Flynn KarenDirectorDec 16Buy6.718005,364800Dec 19 04:27 PM
Weisman WayneDirectorDec 16Buy6.573,00019,7107,000Dec 19 04:28 PM
Weisman WayneDirectorDec 15Buy6.534,00026,1204,000Dec 19 04:28 PM
ALTOMARI ALFREDDirectorDec 15Buy6.551,5009,8251,500Dec 16 04:52 PM
Broadfin Healthcare Master Fun10% OwnerDec 13Buy6.00650,0003,900,0003,100,086Dec 14 03:15 PM